Bevacizumab
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Zaltrap · Afli
VEGF trap · approved 2012 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A soluble VEGF trap that, like bevacizumab, hits the glomerulus with hypertension, proteinuria and TMA.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hypertension and proteinuria are common class effects; in the registrational VELOUR trial, grade 3-4 hypertension and proteinuria were more frequent with aflibercept plus FOLFIRI than with FOLFIRI alone. Nephrotic-range proteinuria and renal thrombotic microangiopathy are documented, including with the ophthalmic formulation, indicating a direct VEGF-trap mechanism. A meta-analysis of 15 trials (4,451 patients) put the summary all-grade hypertension incidence at 42.4%.Source: Qi et al., Clin Drug Investig 2014 (meta-analysis, all-grade hypertension 42.4%); Van Cutsem et al., VELOUR (J Clin Oncol 2012 / Target Oncol 2016)
Within weeks to a few months of therapy.
Distilled from: “Within weeks to a few months of therapy.”
Hypertension, proteinuria and the renal-limited TMA typically improve after the drug is stopped; per label the drug is suspended for proteinuria >=2 g/24 h and resumed at lower dose once <2 g/24 h, and biopsy-proven aflibercept-associated TMA with nephrotic-range proteinuria has completely resolved months after discontinuation.PMID 36309669 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
All-grade hypertension 44.2% (95% CI 39.7-48.7) and grade III/IV 22.6%, pooled from the single-arm studies of a 10-study (2,889-patient) meta-analysis of aflibercept plus chemotherapy in metastatic colorectal cancer; in its randomized trials, OR 6.30 vs control.
Not the same figure as §01's 42.4%. §01 pools 15 trials across cancers; this row pools only the single-arm colorectal-cancer studies of aflibercept plus chemotherapy.
All-grade proteinuria 31.3% (95% CI 19.3-43.3), grade III/IV 7.4% (VEGF-trap podocyte injury), from the same aflibercept mCRC meta-analysis.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Recombinant fusion protein combining the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2 fused to the Fc of human IgG1, acting as a high-affinity soluble decoy that binds and sequesters VEGF-A, VEGF-B and placental growth factor (PlGF), blocking their interaction with native receptors and inhibiting angiogenesis. Used with FOLFIRI in metastatic colorectal cancer previously treated with an oxaliplatin regimen.
Class-level context for the major non-renal toxicities of the VEGF trap class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Oct 2025) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage modification is recommended for patients with renal impairment [see Clinical Pharmacology (12.3) ] .
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 32,703 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
9,101 of 32,703 reports
Reported with hospitalization
4,638 of 32,703 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,943 of the 32,703 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ziv-aflibercept sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
Votrient · VEGFR TKI
VEGFR-TKI; hypertension, proteinuria, TMA.
Inlyta · VEGFR TKI
Potent VEGFR-TKI; hypertension and proteinuria dominate.
Ofev · VEGFR/FGFR/PDGFR TKI
Proteinuria and rare TMA.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.